Table of Contents Author Guidelines Submit a Manuscript
Retracted

BioMed Research International has retracted this article. As noted by Amanda Capes-Davis on PubMed Commons, KB cells are cross-contaminated by HeLa and are not oral cancer cells [2]. Therefore, the conclusions cannot be supported. Tan IIA was already known to induce apoptosis in HeLa cells through a mitochondria-dependent pathway [3].

View the original article here.

References

  1. P.-Y. Tseng, W.-C. Lu, M.-J. Hsieh, S.-Y. Chien, and M.-K. Chen, “Tanshinone IIA induces apoptosis in human oral cancer KB cells through a mitochondria-dependent pathway,” BioMed Research International, vol. 2014, Article ID 540516, 7 pages, 2014.
  2. T. Chen, “Modal karyotype of human leukemia cell line, K562 (ATCC CCL 243),” Cancer Genetics and Cytogenetics, vol. 17, no. 1, pp. 55–60, 1985.
  3. L. Zhou, W. K. Chan, N. Xu et al., “Tanshinone IIA, an isolated compound from Salvia miltiorrhiza Bunge, induces apoptosis in HeLa cells through mitotic arrest,” Life Sciences, vol. 83, no. 11-12, pp. 394–403, 2008.
BioMed Research International
Volume 2014 (2014), Article ID 540516, 7 pages
http://dx.doi.org/10.1155/2014/540516
Research Article

Tanshinone IIA Induces Apoptosis in Human Oral Cancer KB Cells through a Mitochondria-Dependent Pathway

1Department of Otorhinolaryngology, Head and Neck Surgery, Changhua Christian Hospital, No. 135 Nanxiao Street, Changhua 500, Taiwan
2Cancer Research Center, Changhua Christian Hospital, Changhua 500, Taiwan
3Institute of Medicine, Chung Shan Medical University, Taichung 500, Taiwan
4School of Optometry, Chung Shan Medical University, Taichung 402, Taiwan
5Department of Pharmacy, Changhua Christian Hospital, No. 135 Nanxiao Street, Changhua 500, Taiwan
6School of Pharmacy, China Medical University, Taichung 404, Taiwan
7College of Health Sciences, Chang Jung Christian University, Tainan 711, Taiwan

Received 26 February 2014; Accepted 12 April 2014; Published 13 May 2014

Academic Editor: Tsung-Lin Yang

Copyright © 2014 Pao-Yu Tseng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Warnakulasuriya, “Global epidemiology of oral and oropharyngeal cancer,” Oral Oncology, vol. 45, no. 4-5, pp. 309–316, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Jemal, R. Siegel, J. Xu, and E. Ward, “Cancer statistics, 2010,” CA: A Cancer Journal for Clinicians, vol. 60, no. 5, pp. 277–300, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. D. J. Adelstein, Y. Li, G. L. Adams et al., “An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer,” Journal of Clinical Oncology, vol. 21, no. 1, pp. 92–98, 2003. View at Google Scholar · View at Scopus
  4. A. Psyrri, M. Kwong, S. DiStasio et al., “Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up,” Journal of Clinical Oncology, vol. 22, no. 15, pp. 3061–3069, 2004. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Rinehart, T. Ruff, A. Cheung et al., “Neoadjuvant and concomitant chemotherapy and radiation therapy in patients with advanced head and neck carcinoma,” Otolaryngology—Head and Neck Surgery, vol. 132, no. 1, pp. 69–74, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. C. M. Nutting, S. A. Bhide, and K. J. Harrington, “Treatment of head and neck cancer,” The New England Journal of Medicine, vol. 358, no. 10, pp. 1076–1077, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. J.-P. Pignon, A. L. Maître, E. Maillard, and J. Bourhis, “Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients,” Radiotherapy and Oncology, vol. 92, no. 1, pp. 4–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. M. S. Kies, F. C. Holsinger, J. J. Lee et al., “Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 8–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. N. Kumar, “Taxol-induced polymerization of purified tubulin. Mechanism of action,” The Journal of Biological Chemistry, vol. 256, no. 20, pp. 10435–10441, 1981. View at Google Scholar · View at Scopus
  10. S. J. Clarke and L. P. Rivory, “Clinical pharmacokinetics of docetaxel,” Clinical Pharmacokinetics, vol. 36, no. 2, pp. 99–114, 1999. View at Google Scholar · View at Scopus
  11. R. Hitt, A. López-Pousa, J. Martínez-Trufero et al., “Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8636–8645, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. M. R. Posner, D. M. Hershock, C. R. Blajman et al., “Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer,” The New England Journal of Medicine, vol. 357, no. 17, pp. 1705–1715, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. J. H. Lorch, O. Goloubeva, R. I. Haddad et al., “Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial,” The Lancet Oncology, vol. 12, no. 2, pp. 153–159, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Fu, H. Huang, J. Liu, R. Pi, J. Chen, and P. Liu, “Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis,” European Journal of Pharmacology, vol. 568, no. 1–3, pp. 213–221, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. Y.-I. Li, G. Elmer, and R. C. LeBoeuf, “Tanshinone IIA reduces macrophage death induced by hydrogen peroxide by upregulating glutathione peroxidase,” Life Sciences, vol. 83, no. 15-16, pp. 557–562, 2008. View at Publisher · View at Google Scholar · View at Scopus
  16. H. J. Sung, S. M. Choi, Y. Yoon, and K. S. An, “Tanshinone IIA, an ingredient of Salvia miltiorrhiza BUNGE, induces apoptosis in human leukemia cell lines through the activation of caspase-3,” Experimental and Molecular Medicine, vol. 31, no. 4, pp. 174–178, 1999. View at Google Scholar · View at Scopus
  17. L. Zhou, W. K. Chan, N. Xu et al., “Tanshinone IIA, an isolated compound from Salvia miltiorrhiza Bunge, induces apoptosis in HeLa cells through mitotic arrest,” Life Sciences, vol. 83, no. 11-12, pp. 394–403, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Sairafianpour, J. Christensen, D. Steerk et al., “Leishmanicidal, antiplasmodial, and cytotoxic activity of novel diterpenoid 1,2-quinones from Perovskia abrotanoides: new source of tanshinones,” Journal of Natural Products, vol. 64, no. 11, pp. 1398–1403, 2001. View at Publisher · View at Google Scholar · View at Scopus
  19. L.-J. Yang, C.-J. Jeng, H.-N. Kung et al., “Tanshinone IIA isolated from Salvia miltiorrhiza elicits the cell death of human endothelial cells,” Journal of Biomedical Science, vol. 12, no. 2, pp. 347–361, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. G. Kroemer, L. Galluzzi, P. Vandenabeele et al., “Classification of cell death: recommendations of the nomenclature committee on cell death 2009,” Cell Death and Differentiation, vol. 16, no. 1, pp. 3–11, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. K. C. Zimmermann, C. Bonzon, and D. R. Green, “The machinery of programmed cell death,” Pharmacology & Therapeutics, vol. 92, no. 1, pp. 57–70, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. P. Li, D. Nijhawan, I. Budihardjo et al., “Cytochrome c and dATP-dependent formation of apaf-1/caspase-9 complex initiates an apoptotic protease cascade,” Cell, vol. 91, no. 4, pp. 479–489, 1997. View at Publisher · View at Google Scholar
  23. D. R. Green and J. C. Reed, “Mitochondria and apoptosis,” Science, vol. 281, no. 5381, pp. 1309–1312, 1998. View at Google Scholar · View at Scopus
  24. I. Budihardjo, H. Oliver, M. Lutter, X. Luo, and X. Wang, “Biochemical pathways of caspase activation during apoptosis,” Annual Review of Cell and Developmental Biology, vol. 15, pp. 269–290, 1999. View at Publisher · View at Google Scholar · View at Scopus
  25. X. Wang, “The expanding role of mitochondria in apoptosis,” Genes and Development, vol. 15, no. 22, pp. 2922–2933, 2001. View at Google Scholar · View at Scopus
  26. M. Sebbagh, C. Renvoizé, J. Hamelin, N. Riché, J. Bertoglio, and J. Bréard, “Caspase-3-mediated cleavage of ROCK I induces MLC phosphorylation and apoptotic membrane blebbing,” Nature Cell Biology, vol. 3, no. 4, pp. 346–352, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. D. W. Nicholson, A. Ali, N. A. Thornberry et al., “Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis,” Nature, vol. 376, no. 6535, pp. 37–43, 1995. View at Google Scholar · View at Scopus
  28. W. Hu and J. J. Kavanagh, “Anticancer therapy targeting the apoptotic pathway,” The Lancet Oncology, vol. 4, no. 12, pp. 721–729, 2003. View at Publisher · View at Google Scholar · View at Scopus
  29. E. R. McDonald 3rd. and W. S. El-Deiry, “Cell cycle control as a basis for cancer drug development (review),” International Journal of Oncology, vol. 16, no. 5, pp. 871–886, 2000. View at Google Scholar · View at Scopus
  30. G. K. Schwartz and M. A. Shah, “Targeting the cell cycle: a new approach to cancer therapy,” Journal of Clinical Oncology, vol. 23, no. 36, pp. 9408–9421, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. S. Yuan, Y. Wang, X. Chen, Y. Song, and Y. Yang, “A study on apoptosis of nasopharyngeal carcinoma cell line induced by Tanshinone II A and its molecular mechanism,” Hua Xi Yi Ke Da Xue Xue Bao, vol. 33, no. 1, pp. 84–90, 2002. View at Google Scholar · View at Scopus
  32. S.-L. Yuan, Y.-Q. Wei, X.-J. Wang, F. Xiao, S.-F. Li, and J. Zhang, “Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells,” World Journal of Gastroenterology, vol. 10, no. 14, pp. 2024–2028, 2004. View at Google Scholar · View at Scopus
  33. K. N. Bhalla, “Microtubule-targeted anticancer agents and apoptosis,” Oncogene, vol. 22, no. 56, pp. 9075–9086, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. F. Mollinedo and C. Gajate, “Microtubules, microtubule-interfering agents and apoptosis,” Apoptosis, vol. 8, no. 5, pp. 413–450, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. B. C. Barnhart, J. C. Lee, E. C. Alappat, and M. E. Peter, “The death effector domain protein family,” Oncogene, vol. 22, no. 53, pp. 8634–8644, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. J. M. Adams and S. Cory, “Life-or-death decisions by the bcl-2 protein family,” Trends in Biochemical Sciences, vol. 26, no. 1, pp. 61–66, 2001. View at Publisher · View at Google Scholar · View at Scopus
  37. L. Scorrano, S. A. Oakes, J. T. Opferman et al., “BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis,” Science, vol. 300, no. 5616, pp. 135–139, 2003. View at Publisher · View at Google Scholar · View at Scopus